Ceftizoxime + SulbactamThird Party Manufacturing in India

Ceftizoxime + Sulbactam works by executing a dual-action mechanism against bacterial resistance. Ceftizoxime blocks cell wall assembly by targeting penicillin-binding proteins, causing structural damage. Sulbactam serves as a protector by binding irreversibly to bacterial beta-lactamase enzymes, neutralizing their destructive capabilities. Unlike single cephalosporin agents, this blend completely restores efficacy against beta-lactamase-producing clinical strains. It is highly effective and well-tolerated.

Therapeutic Uses

• Intra-Abdominal Sepsis: Prescribed for polymicrobial infections involving beta-lactamase-producing strains.
• Gynecological Infections: Effective against resistant pelvic infections and post-surgical complications.
• Complicated Urinary Infections: Deployed when single antibiotics fail due to enzyme-mediated resistance.
• Septicemia Management: Used to secure rapid clinical clearance of multi-drug resistant bacterial strains in blood stream infections.

Why Manufacturers Choose Ceftizoxime + Sulbactam

Selecting Ceftizoxime + Sulbactam third party manufacturing in India helps brands tap into an exclusive, high-margin antibiotic sector. Incorporating the primary core compound under CAS number 68401-81-0 ensures predictable pharmacological action and high therapeutic success rates. Our partner facilities are WHO-GMP certified, which means the production follows strict adherence to quality assurance models. Offering this advanced combination under a verified WHO-GMP standard strengthens any corporate healthcare portfolio.